Table 2 CAR-T cell-related complications and management in the ICU

Isolated cytokine release syndrome

33 (46%)

 Grade 1

10

 Grade 2

17

 Grade 3

6

Time between CRS and ICU admission (days)

2 [1–3]

Neurotoxicity

26 (37%)

 Grade 1

4/26 (15%)

 Grade 2

5/26 (19%)

 Grade 3

3/26 (11%)

 Grade 4

14/26 (54%)

 Time between ICU admission and worst neurotoxicity grade (days)

1 [0–1]

Documented bacterial infection

21 (30%)

 Site of infection

 Catheter-related infection

15/21 (71%)

 Digestive/biliary tract

4/21 (19%)

 Urinary tract

1/21 (5%)

 Unknown

1/21 (5%)

Bacteria

 Coagulase negative Staphylococcus

13

 Enterobacteriaceae

3

 Pseudomonas aeruginosa

1

 Enterococcus faecium

1

 Clostridium difficile

2

 Paracoccus yeei

1

Specific treatments

 Tocilizumab

49 (69%)

 Median dosage (mg)

800 [560–1480]

 Median number of injections

1 [1–2]

 Time between ICU admission and tocilizumab (hours)

5 [2–15]

 Steroids

40 (56%)

 Time between ICU admission and steroids (hours)

23 [5–34]

 Siltuximab

9 (12.6%)

 Anakinra

2 (2.8%)

Non-specific treatments in the ICU

 Fluid resuscitation at day 1 (mL)

500 [0–1750]

 Broad spectrum antibiotics

70 (98%)

 Vasopressors

20 (28%)

 Mechanical ventilation

4 (6%)

 Renal replacement therapy

1 (1.5%)

Outcome

 Death in the ICU

1 (1.5%)

 Death in the hospital

8 (12%)

 Death at last follow-up

26 (37%)

 Median follow-up (months)

6 [2–15]